Sexually transmitted infection

binx health Announces Strategic Supply Agreement with Afaxys to Expand Sexual Health Test Access to Thousands of Clinics Nationally

Retrieved on: 
Thursday, November 10, 2022
Women, Other Science, Medical Supplies, FDA, General Health, Logistics, Supply Chain Management, Public Policy, Government, Consumer, Healthcare Reform, Medical Devices, Infectious Diseases, Health Technology, LGBTQ+, Transport, AIDS, University, Health, Education, State, Local, Science, CT, University, Pre-exposure prophylaxis, GPO, Gonorrhea, Health, Community, Sexually transmitted infection, HIV, Associated Press, FDA, Partnership, Risk, Binx, Organization, Technology, Diagnosis, NG, CDC, Man, Parenthood, Chlamydia, United, STD, Health equity, Patient, Public health, Health minister, Woman, STI, Infection, Group purchasing organization, Pharmaceutical industry, Birth control, Medical device

binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced a strategic agreement with Afaxys Group Services LLC to expand access to sexual health and wellness testing nationally through their Group Purchasing Organization (GPO) .

Key Points: 
  • binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced a strategic agreement with Afaxys Group Services LLC to expand access to sexual health and wellness testing nationally through their Group Purchasing Organization (GPO) .
  • Under the agreement, binx will offer its FDA-cleared, CLIA-waived point-of-care test for chlamydia (CT) and gonorrhea (NG) and its at-home digital health platform to thousands of clinics across the United States, under a preferred pricing model with joint marketing outreach among Afaxys and binx.
  • With this agreement, we will be able to help more patients receive the tests they need in a way that works best for them.
  • We applaud the important work of Afaxys and its member clinics in furthering healthcare access and are thrilled to join their GPO network, said Jeffrey Luber, Chief Executive Officer of binx health.

InventHelp Inventor Develops New Prophylactic to Increase Sexual Satisfaction (LJD-197)

Retrieved on: 
Thursday, November 3, 2022
Man, Sexually transmitted infection, Vertically transmitted infection, Condom, STD, Pregnancy, Sale, Multimedia, Ninth Street, Birth control

My design could offer a heightened, more satisfying sexual experience and it would help to protect against STD's and pregnancies."

Key Points: 
  • My design could offer a heightened, more satisfying sexual experience and it would help to protect against STD's and pregnancies."
  • The patent-pending invention provides an improved prophylactic to increase sexual satisfaction.
  • It also provides an alternative to traditional condoms and it helps to protect against pregnancy and sexually transmitted diseases.
  • The original design was submitted to the Long Island sales office of InventHelp.

Lucira Health to Announce Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 1, 2022
Patient, Lucira, STI, AA, GLOBE, Sexually transmitted infection, Webcast, EUA, COVID-19, Hand, Urinary tract infection, NAAT, Pharmaceutical industry

EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Lucira Health or Lucira), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022.

Key Points: 
  • EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Lucira Health or Lucira), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022.
  • ET that day to discuss the financial results and provide a corporate update.
  • Each Lucira test contains everything needed to run a single COVID-19 test: the test device, two AA batteries, sample vial, swab, and simple instructions.
  • Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time.

Black Owned Condom Brand comes with descriptive advice about sexual pleasure.

Retrieved on: 
Wednesday, November 2, 2022
Human, CEO, Orgasm, The New York Times, Giant panda, Pulse, Condom, Pleasure, Social media, Sexually transmitted infection, Platinum, CDC, African Americans, USA Today, Birth control

ATLANTA, Nov. 2, 2022 /PRNewswire/ -- For B Condoms there is no competition and no crowded marketplace. There is a new king of condoms in town and that is Jason Panda, Founder and CEO. Jason has created the perfect protection with the perfect platinum packaging. It is leading the pack on performance, power, and protection.

Key Points: 
  • Black Owned Condom Brand comes with descriptive advice about sexual pleasure.
  • The brand is focused on targeting Black Americans; however, it is available to all.
  • Jason's plan is to push social media platforms that discuss sexuality and sexual wellness in frank terms.
  • Sex educators like that the post has a practical bent which makes the brand and the product stand out.

InventHelp Inventor Develops New Prophylactic to Increase Sexual Satisfaction (LJD-197)

Retrieved on: 
Thursday, October 20, 2022
Vertically transmitted infection, Sexually transmitted infection, Sale, Ninth Street, Man, Pregnancy, STD, Multimedia, Condom, Birth control

My design could offer a heightened, more satisfying sexual experience and it would help to protect against STD's and pregnancies."

Key Points: 
  • My design could offer a heightened, more satisfying sexual experience and it would help to protect against STD's and pregnancies."
  • The patent-pending invention provides an improved prophylactic to increase sexual satisfaction.
  • It also provides an alternative to traditional condoms and it helps to protect against pregnancy and sexually transmitted diseases.
  • The original design was submitted to the Long Island sales office of InventHelp.

Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics

Retrieved on: 
Thursday, October 6, 2022
Method, Public relations, COVID, Monocyte, PCR, RP, Legislation, CEO, Sexually transmitted infection, Amazon, TBIA, Cell cycle, Solution, Cancer, Lymphocyte, STI, TMB-2, Neurodegeneration, Accountable care organization, Knowledge, Company, CyberGraphX, GLOBE, TEL, Pathology, Research, Collection, Technology, Alzheimer's disease, Urinary tract infection, Monkeypox, Apoptosis, OTCQB, Pressure, Physician, U.S. Securities and Exchange Commission, Quest Diagnostics, Biotechnology, Cancer prevention, UTI, Synthase, Immune system, Neuron, Acquisition, Brain, Plasma, Pharmaceutical industry, Medical imaging, Pharma, Long COVID

NEW YORK, NY and TEL AVIV, Israel, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP laboratory, Provista Diagnostics , has successfully completed a pilot launch of the Companys Suite of PCR Testing services in the rural city of Dunnellon, Florida.

Key Points: 
  • NEW YORK, NY and TEL AVIV, Israel, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP laboratory, Provista Diagnostics , has successfully completed a pilot launch of the Companys Suite of PCR Testing services in the rural city of Dunnellon, Florida.
  • The PCR testing services include Urinary Tract Infection (UTI), Wound, Respiratory Pathogen (RP), Gastrointestinal (GI), Sexually Transmitted Infections (STI), COVID and MonkeyPox panels.
  • Provista has now officially expanded beyond COVID testing and is beginning to generate an increasing part of its revenue from non-COVID related testing, said Gerald Commissiong, President & CEO of Provista Diagnostics and Todos Medical, Provistas parent company.
  • Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics , Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Pane l analyses, and Provista's proprietary commercial-stage Videssa breast cancer blood test.

Lucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays

Retrieved on: 
Thursday, September 29, 2022
Chlamydia trachomatis, MPH, National, Risk, Neisseria gonorrhoeae, Infection, COVID-19, Woman, STI, Organic acid, LAMP, Cepheid variable, Neisseria, Ministry, Urinary tract infection, Growth, Private Securities Litigation Reform Act, Lucira, Maintenance, Forward-looking statement, U.S. Securities and Exchange Commission, Technology, University of California, San Francisco, Female, POCT, San Francisco, CDC, Annual report, Nasdaq, UC, Research, Security (finance), GLOBE, Marketing, Sexually transmitted infection, Pharmaceutical industry, Birth control, MD, Chlamydia, Health

EMERYVILLE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (Lucira Health or Lucira), a medical technology company, today announced interim results of a pilot study to evaluate the performance of their combined Chlamydia trachomatis and Neisseria gonorrhoeae assays integrated into the instrument-free at-home Lucira molecular test platform.

Key Points: 
  • EMERYVILLE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (Lucira Health or Lucira), a medical technology company, today announced interim results of a pilot study to evaluate the performance of their combined Chlamydia trachomatis and Neisseria gonorrhoeae assays integrated into the instrument-free at-home Lucira molecular test platform.
  • The ongoing study has tested over 150 female participants with positive performance results of the integrated chlamydia and gonorrhea tests and will be published in the near future.
  • Lucira is integrating these STI assays into its easy-to-use fully untethered test platform that requires no external equipment and produces rapid molecular results on-the-spot.
  • Its an honor to have world renowned principal investigator, Deborah Dean, MD, MPH, leading the clinical trials for Luciras chlamydia and gonorrhea assays, said Debkishore Mitra, Ph.D, Chief Technology Officer and Co-Founder at Lucira Health.

AHF Condemns Texas Ruling Denying PrEP Coverage

Retrieved on: 
Thursday, September 8, 2022
LGBTQ+, AIDS, Courts, Health, Healthcare Reform, Public Policy, Pharmaceutical, Other Policy Issues, Infectious Diseases, Public Policy, Government, Consumer, AIDS Healthcare Foundation, AHF, Sexually transmitted infection, AIDS, HPV, District court, Vaccine, Freedom, Religion, Birth, Provisions of the Affordable Care Act, HIV, Religious Freedom Restoration Act, Instagram, Twitter, Facebook, Care Act 2014, Patient, Health insurance

AIDS Healthcare Foundation ( AHF ) strongly condemns the decision of U.S. District Court Judge Reed OConnor in the Northern District of Texas that would allow private employers to deny access to HIV prevention medication based on the Religious Freedom Restoration Act.

Key Points: 
  • AIDS Healthcare Foundation ( AHF ) strongly condemns the decision of U.S. District Court Judge Reed OConnor in the Northern District of Texas that would allow private employers to deny access to HIV prevention medication based on the Religious Freedom Restoration Act.
  • The judge ruled on September 7th that a provision of the Affordable Care Act that mandates free coverage of certain drugs violates the religious beliefs of a Christian-owned company.
  • The judges ruling gives private employers the ability to opt out of providing access to pre-exposure prophylaxis (PrEP) medication that prevents the transmission of HIV.
  • said Michael Weinstein, President of AHF.

SESAME ANNOUNCES 'BUY ONE, GET ONE FREE" PRICING FOR SEXUALLY TRANSMITTED DISEASE (STD) TESTING

Retrieved on: 
Wednesday, September 7, 2022
Virgin Group, Sex, Ageing, Quest Diagnostics, Health minister, Friends, Doctor of Philosophy, Man, Sexually transmitted infection, Centers for Disease Control and Prevention, General Catalyst, Goldman Sachs, Healthline, Physician, Health, Economics, GV, Infection, Student, NEW, Harvard University, Health policy, Center, STD, Plasma protein binding, Woman, COVID, CDC, Patient, Management, Tutoring, Birth control, Health insurance, Sesame, Atlantic Ocean

NEW YORK, Sept. 7, 2022 /PRNewswire/ -- Sesame, the company building a radically new healthcare system for uninsured and underserved Americans by directly connecting them to high-quality physicians at half the price, today announced promotional pricing for its Sexually Transmitted Disease (STD) lab tests, just in time for the opening of college campuses and dormitories.

Key Points: 
  • For a limited time, Sesame is here to help the one-in-four college students who are believed to be affected.
  • With that in mind, Sesame is offering special STD lab test pricing through May 31, 2023.
  • Testing and test results obtained through the Sesame marketplace are private, discreet and compliant with all HIPAA provisions.
  • This online survey of 500 current college students was commissioned by Sesame and conducted by market research company Pollfish.

Global Female Sterilization Devices Market Report 2022 Size, Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecasts, 2015-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 2, 2022
Medical Devices, Health, STD, Region, Male, SWOT, Female, ASP, Risk, Sexually transmitted infection, Sterilization, Income, COVID-19, Epidemiology, Country, Vasectomy, Tubing (recreation), Market access, SWOT analysis, Birth control, Retail, Healthcare, Forecast

The "Female Sterilization Devices Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Female Sterilization Devices Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030" report has been added to ResearchAndMarkets.com's offering.
  • Female Sterilization Devices Market report is built to visualize quantitative market trends within Reproductive Health Devices therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Female Sterilization Devices market for the year 2020 and beyond.
  • Global, Regional and Country level market specific insights:
    Qualitative market specific information is available with global trends further broken down into regional trends.